Mauad Edmundo Carvalho, do Rosario Dias de Oliveira Latorre Maria, Silva Thiago Buosi, Daher Ricardo Mauad, de Lima Vazquez Vinicius, Oliveira Antonio Talvane Torres, Filho Adhemar Longatto
Barretos Cancer Hospital, Department of Cancer Screening, Sao Paulo, Brazil.
Laboratory of Medical Investigation (LIM) 14 of Department of Pathology of Medical School of Sao Paulo University, Sao Paulo, Brazil.
World J Oncol. 2010 Feb;1(1):35-41. doi: 10.4021/wjon2010.02.193w. Epub 2010 Feb 1.
Esophagic cancer incidence is extremely variable worldwide. Also, the global survival rate has not oscillated significantly since last decade. Most of the worse prognoses are found among patients with advanced stages. Despite that, around 10% of cases occur in patients with initial stage, which strongly associate these patients with unfavorable prognosis. We sought to analyze the impact of time free of disease and global survival rates of patients with initial stage of esophagic cancer.
We studied 18 patients with initial stage of esophagic cancer (stage 0 and I), examined and treated at Hospital de Cancer de Barretos between 1990 and 2005.
The vast majority of patients were male (83.3%) with age up to 49 yarest old (77.8%), squamous cell carcinoma (SCC) (88.9%) and stage I (83.3%). Most of them were smoker (60.0%) and etilist (62.5%). There were 38.9% of the patients with comorbities like dysphagia and epigastralgia correlated to other pathological conditions. We found free disease rates of 100% and 82.5%, respectively for 12 and 36 months. The significant prognostic evidence was the age, epigastralgia symptoms and chemotherapy. From 18 patients, 6 passed away during the period of 36 months follow up due to cancer consequences. The probabilities of global survival were 76.7% and 64.4% after 12 and 36 months, respectively, and none of the analyzed variables influenced in theses rates.
Our data ratifies those from previous reported. The global survival rates were worse than reported by literature, maybe in consequence of the poor clinical condition of many patients which limited the option for more aggressive therapy.
食管癌发病率在全球范围内差异极大。此外,自上一个十年以来,全球生存率并无显著波动。大多数预后较差的情况见于晚期患者。尽管如此,约10%的病例发生在早期患者中,而这些患者的预后通常不佳。我们试图分析食管癌早期患者的无病生存期和总生存率的影响因素。
我们研究了1990年至2005年间在巴雷托斯癌症医院接受检查和治疗的18例食管癌早期(0期和I期)患者。
绝大多数患者为男性(83.3%),年龄最大49岁(77.8%),为鳞状细胞癌(SCC)(88.9%)且处于I期(83.3%)。他们中的大多数人吸烟(60.0%)且饮酒(62.5%)。38.9%的患者伴有吞咽困难和上腹部疼痛等合并症,这些与其他病理状况相关。我们发现12个月和36个月时的无病生存率分别为100%和82.5%。显著的预后证据是年龄、上腹部疼痛症状和化疗。在18例患者中,6例在36个月的随访期内因癌症相关后果死亡。12个月和36个月后的总生存率分别为76.7%和64.4%,且所分析的变量均未对这些生存率产生影响。
我们的数据证实了先前报道的结果。总生存率低于文献报道,这可能是由于许多患者临床状况较差,限制了更积极治疗的选择。